Concise Review: Mesenchymal Stem Cell Treatment of the Complications of Diabetes Mellitus

Abstract

Mesenchymal stem cells (MSCs) are multipotent, self-renewing cells that can be found in almost all postnatal organs and tissues. The main functional characteristics of MSCs are their immunomodulatory ability, capacity for self-renewal, and differentiation into mesodermal tissues. The ability of MSCs to differentiate into several cell types, including muscle, brain, vascular, skin, cartilage, and bone cells, makes them attractive as therapeutic agents for a number of diseases including complications of diabetes mellitus. We review here the potential of MSCs as new therapeutic agents in the treatment of diabetic cardiomyopathy, diabetic nephropathy, diabetic polyneuropathy, diabetic retinopathy, and diabetic wounds. Also, in this review we discuss the current limitations for MSCs therapy in humans.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 46

1. 1.

   Porada CD, Zanjani ED, Almeida-Porad G. Adult mesenchymal stem cells: A pluripotent population with multiple applications. Curr Stem Cell Res Ther. 2006;1:365-369.

   Not in our library10.2174/157488806778226821

2. 2.

   da Silva Meirelles L, Chagastelles PC, Nardi NB. Mesenchymal stem cells reside in virtually all post-natal organs and tissues. J Cell Sci. 2006;119(part 11):2204-2213.

   Not in our library10.1242/jcs.02932

3. 3.

   Chamberlain G, Fox J, Ashton B, et al. Concise review: Mesenchymal stem cells: Their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells. 2007;25:2739-2749.

   Not in our library10.1634/stemcells.2007-0197

4. 4.

   Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8:315-317.

   Not in our library10.1080/14653240600855905

5. 5.

   Prockop DJ. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science. 1997;276:71-74.

   Not in our library10.1126/science.276.5309.71

6. 6.

   Abdi R, Fiorina P, Adra CN, et al. Immunomodulation by mesenchymal stem cells: A potential therapeutic strategy for type 1 diabetes. Diabetes. 2008;57:1759-1767.

   Not in our library10.2337/db08-0180

7. 7.

   Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal stromal cells. Blood. 2007;110:3499-3506.

   Not in our library10.1182/blood-2007-02-069716

8. 8.

   Volarevic V, Al-Qahtani A, Arsenijevic N, et al. Interleukin-1 receptor antagonist (IL-1Ra) and IL-1Ra producing mesenchymal stem cells as modulators of diabetogenesis. Autoimmunity. 2010;43:255-263.

   Not in our library10.3109/08916930903305641

9. 9.

   Zdravkovic N, Shahin A, Arsenijevic N, et al. Regulatory T cells and ST2 signaling control diabetes induction with multiple low doses of streptozotocin. Mol Immunol. 2009;47:28-36.

   Not in our library10.1016/j.molimm.2008.12.023

10. 10.

    Mensah-Brown EP, Shahin A, Al-Shamisi M, et al. IL-23 leads to diabetes induction after subdiabetogenic treatment with multiple low doses of streptozotocin. Eur J Immunol. 2006;36:216-223.

    Not in our library10.1002/eji.200535325

11. 11.

    Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284:143-147.

    Not in our library10.1126/science.284.5411.143

12. 12.

    Xie QP, Huang H, Xu B, et al. Human bone marrow mesenchymal stem cells differentiate into insulin-producing cells upon microenvironmental manipulation in vitro. Differentiation. 2009;77:483-491.

    Not in our library10.1016/j.diff.2009.01.001

13. 13.

    Sun Y, Chen L, Hou XG, et al. Differentiation of bone marrow-derived mesenchymal stem cells from diabetic patients into insulin-producing cells in vitro. Chin Med J. 2007;120:771-776.

    Not in our library

14. 14.

    Tang DQ, Cao LZ, Burkhardt BR, et al. In vivo and in vitro characterization of insulin-producing cells obtained from murine bone marrow. Diabetes. 2004;53:1721-1732.

    Not in our library10.2337/diabetes.53.7.1721

15. 15.

    Chen LB, Jiang XB, Yang L. Differentiation of rat marrow mesenchymal stem cells into pancreatic islet beta-cells. World J Gastroenterol. 2004;10:3016-3020.

    Not in our library10.3748/wjg.v10.i20.3016

16. 16.

    Poornima IG, Parikh P, Shannon RP. Diabetic cardiomyopathy: The search for a unifying hypothesis. Circ Res. 2006;98:596-605.

    Not in our library10.1161/01.res.0000207406.94146.c2

17. 17.

    Jesmin S, Sakuma I, Hattori Y, et al. Role of angiotensin II in altered expression of molecules responsible for coronary matrix remodeling in insulin-resistant diabetic rats. Arterioscler Thromb Vasc Biol. 2003;23:2021-2026.

    Not in our library10.1161/01.atv.0000094235.78783.d1

18. 18.

    Camp TM, Tyagi SC, Senior RM, et al. Gelatinase B (MMP-9) an apoptotic factor in diabetic transgenic mice. Diabetologia. 2003;46:1438-1445.

    Not in our library10.1007/s00125-003-1200-y

19. 19.

    Yoon YS, Uchida S, Masuo O, et al. Progressive attenuation of myocardial vascular endothelial growth factor expression is a seminal event in diabetic cardiomyopathy: Restoration of microvascular homeostasis and recovery of cardiac function in diabetic cardiomyopathy after replenishment of local vascular endothelial growth factor. Circulation. 2005;111:2073-2085.

    Not in our library10.1161/01.cir.0000162472.52990.36

20. 20.

    Zhang N, Li J, Luo R, et al. Bone marrow mesenchymal stem cells induce angiogenesis and attenuate the remodeling of diabetic cardiomyopathy. Exp Clin Endocrinol Diabetes. 2008;116:104-111.

    Not in our library10.1055/s-2007-985154

21. 21.

    Wang X, Zhao T, Huang W, et al. Hsp20-engineered mesenchymal stem cells are resistant to oxidative stress via enhanced activation of Akt and increased secretion of growth factors. Stem Cells. 2009;27:3021-3031.

    Not in our library10.1002/stem.230

22. 22.

    Hare JM, Traverse JH, Henry TD, et al. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol. 2009;54:2277-2286.

    Not in our library10.1016/j.jacc.2009.06.055

23. 23.

    Lee JS, Hong JM, Moon GJ, et al. A long-term follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke. Stem Cells. 2010;28:1099-1106.

    Not in our library10.1002/stem.430

24. 24.

    Amin AH, Abd Elmageed ZY, Nair D, et al. Modified multipotent stromal cells with epidermal growth factor restore vasculogenesis and blood flow in ischemic hind-limb of type II diabetic mice. Lab Invest. 2010;90:985-996.

    Not in our library10.1038/labinvest.2010.86

25. 25.

    Comerota AJ, Link A, Douville J, et al. Upper extremity ischemia treated with tissue repair cells from adult bone marrow. J Vasc Surg. 2010;52:723-739.

    Not in our library10.1016/j.jvs.2010.04.020

26. 26.

    Fazan R, Dias da Silva VJ, Ballejo G, et al. Power spectra of arterial pressure and heart rate in streptozotocin-induced diabetes in rats. J Hypertens. 1999;17:489-495.

    Not in our library10.1097/00004872-199917040-00006

27. 27.

    Fazan R, Ballejo G, Salgado MC, et al. Heart rate variability and baroreceptor function in chronic diabetic rats. Hypertension. 1997;30:632-635.

    Not in our library10.1161/01.hyp.30.3.632

28. 28.

    Stroedter D, Schmidt T, Bretzel RG, et al. Glucose metabolism and left ventricular dysfunction are normalized by insulin and islet transplantation in mild diabetes in the rat. Acta Diabetol. 1995;32:235-243.

    Not in our library10.1007/bf00576256

29. 29.

    Abdel Aziz MT, El-Asmar MF, Haidara M, et al. Effect of bone marrow-derived mesenchymal stem cells on cardiovascular complications in diabetic rats. Med Sci Monit. 2008;14:249-255.

    Not in our library

30. 30.

    Ezquer FE, Ezquer ME, Parrau DB, et al. Systemic administration of multipotent mesenchymal stromal cells reverts hyperglycemia and prevents nephropathy in type 1 diabetic mice. Biol Blood Marrow Transplant. 2008;14:631-640.

    Not in our library10.1016/j.bbmt.2008.01.006

31. 31.

    Lee RH, Seo MJ, Reger RL, et al. Multipotent stromal cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD/scid mice. Proc Natl Acad Sci USA. 2006;103:17438-17443.

    Not in our library10.1073/pnas.0608249103

32. 32.

    Herrera MB, Bussolati B, Bruno S, et al. Mesenchymal stem cells contribute to the renal repair of acute tubular epithelial injury. Int J Mol Med. 2004;14:1035-1041.

    Not in our library

33. 33.

    Vinik AI, Park TS, Stansberry KB, et al. Diabetic neuropathies. Diabetologia. 2000;43:957-973.

    Not in our library10.1007/s001250051477

34. 34.

    Kinnaird T, Stabile E, Burnett MS, et al. Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine mechanisms. Circulation. 2004;109:1543-1549.

    Not in our library10.1161/01.cir.0000124062.31102.57

35. 35.

    Shibata T, Naruse K, Kamiya H, et al. Transplantation of bone marrow-derived mesenchymal stem cells improves diabetic polyneuropathy in rats. Diabetes. 2008;57:3099-3107.

    Not in our library10.2337/db08-0031

36. 36.

    Yang Z, Li K, Yan X, Dong F, et al. Amelioration of diabetic retinopathy by engrafted human adipose-derived mesenchymal stem cells in streptozotocin diabetic rats. Graefes Arch Clin Exp Ophthalmol. 2010;248:1415-1422.

    Not in our library10.1007/s00417-010-1384-z

37. 37.

    Medina A, Scott PG, Ghahary A, et al. Pathophysiology of chronic nonhealing wounds. J Burn Care Rehabil. 2005;26:306-319.

    Not in our library10.1097/01.bcr.0000169887.04973.3a

38. 38.

    Spanheimer RG. Correlation between decreased collagen production in diabetic animals and in cells exposed to diabetic serum: Response to insulin. Matrix. 1992;12:101-107.

    Not in our library10.1016/s0934-8832(11)80051-x

39. 39.

    Kwon DS, Gao X, Liu YB, et al. Treatment with bone marrow-derived stromal cells accelerates wound healing in diabetic rats. Int Wound J. 2008;5:453-463.

    Not in our library10.1111/j.1742-481x.2007.00408.x

40. 40.

    Wu Y, Chen L, Scott PG, et al. Mesenchymal stem cells enhance wound healing through differentiation and angiogenesis. Stem Cells. 2007;25:2648-2659.

    Not in our library10.1634/stemcells.2007-0226

Cited by papers we hold 4

• Mesenchymal stromal cells promote liver regeneration through regulation of immune cells · 2020
  No notice
• Treatment with adipose tissue-derived mesenchymal stem cells exerts anti-diabetic effects, improves long-term complications, and attenuates inflammation in type 2 diabetic rats · 2019
  No notice
• Therapeutic Potential of Mesenchymal Stem Cells in Regenerative Medicine · 2013
  No notice
• Bone-Marrow-Derived Mesenchymal Stromal Cells (MSC) from Diabetic and Nondiabetic Rats Have Similar Therapeutic Potentials
  Not checked

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.